A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

NCT05878561 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Fimasartan + Indapamide
DRUG: Fimasartan + Indapamide placebo

Sponsor

Boryung Pharmaceutical Co., Ltd